July 15 is the date set by the US Bankruptcy Court for the hearing to confirm Cambridge Biotech's plans for reorganization (Marketletters passim). The plan will establish a new firm, Aquila Biopharmaceuticals, which will continue Cambridge's core business of developing and commercializing products to stimulate the immune system to treat infectious diseases and cancer. The plan has been approved by the Court and the firm has solicited acceptance from creditors and shareholders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze